Details of the Drug Reposition

General Information of This Drug (ID: DM8JWNA)

Drug Name
NVP-LAQ824   DM8JWNA
Synonyms
Dacinostat; 404951-53-7; LAQ824; LAQ-824; LAQ824 (Dacinostat); UNII-V10P524501; (E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide; CHEMBL356066; V10P524501; (2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; Dacinostat [INN]; (E)-N-Hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]meth yl]phenyl]prop-2-enamide; (2E)-N-hydroxy-3-(4-{[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl}phenyl)prop-2-enamide; Dacinostat; NVP-LAQ 824; NVP-LAQ824, Dacinostat, LAQ824; LBH539
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Mood disorder DISLVMWO 6A60-6E23 Phase 3 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Discontinued in Phase 2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Multiple myeloma DISEWP9B 2A83 Investigative [2]
------------------------------------------------------------------------------------

References

1 Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
2 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.